ARTICLE | Clinical News

Entasis reports Phase I data for anti-infective ETX2514

October 13, 2017 12:34 AM UTC

Entasis Therapeutics Inc. (Waltham, Mass.) reported data from a double-blind, placebo-controlled, Australian Phase I trial in 124 healthy volunteers showing that single and multiple ascending doses of IV ETX2514 given alone or in combination with sulbactam and/or imipenem/cilastatin were generally well tolerated. The most common adverse events reported were headaches, catheter-site inflammation, mild drowsiness and nausea. Data were presented at the IDWeek meeting in San Diego.

In Phase II, Entasis plans to evaluate ETX2514 in combination with sulbactam to treat Acinetobacter baumannii infections and in combination with imipenem to treat undisclosed Gram-negative infections...

BCIQ Company Profiles

Entasis Therapeutics Inc.

BCIQ Target Profiles

Beta lactamase (LACTB)